At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 45 enrolled
Drug / intervention
Aliskiren +2 moredrug
Likely dose
Aliskiren 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Randomized, Parallel-group Study to Evaluate the Acute and Steady-state Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
In Brief
A Phase 4 clinical trial evaluating Aliskiren, Irbesartan, and 1 other intervention for Type 2 Diabetes Mellitus. Completed, enrolled 45 participants across 1 site.
Detailed Summary
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or irbesartan on renal blood flow, glomerular filtration rate, and retinal blood flow in patients with type 2 diabetes mellitus.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2008
First PostedApr 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedApr 17, 2008
Enrollment StartApr 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 18.2 years ago
Interventions
Aliskirendrug
Aliskiren 300 mg tablets
Irbesartandrug
Irbesartan 300 mg tablets
Captoprildrug
Captopril 25 mg tablet